Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2024-09-13 Sale | 2024-09-17 8:05 pm | Y-mAbs Therapeutics Inc. | YMAB | Gad Thomas CHIEF BUSINESS OFFICER | 95,000 | $13.31 | $1,264,650 | 286,381 (Indirect Direct) | View |
| 2024-08-28 Sale | 2024-08-30 4:15 pm | Y-mAbs Therapeutics Inc. | YMAB | Lund-Hansen Torben SVP & CHIEF TECHNICAL OFFICER | 50,000 | $15.37 | $768,500 | 181,262 (Indirect Direct) | View |
| 2024-08-26 Sale | 2024-08-27 5:05 pm | Y-mAbs Therapeutics Inc. | YMAB | Wilms Joris SVP & CHIEF OPERATING OFFICER | 5,000 | $14.69 | $73,450 | 30,600 (Direct) | View |
| 2024-06-10 Sale | 2024-06-11 7:54 pm | Y-mAbs Therapeutics Inc. | YMAB | Ber Gerard Director | 722 | $12 | $8,664 | 1,608 (Direct) | View |
| 2024-06-10 Sale | 2024-06-11 7:53 pm | Y-mAbs Therapeutics Inc. | YMAB | Gad Thomas CHIEF BUSINESS OFFICER | 70,000 | $12.02 | $841,050 | 381,381 (Indirect Direct) | View |
| 2024-05-30 Sale | 2024-05-31 9:36 pm | Y-mAbs Therapeutics Inc. | YMAB | Kruse Bo EVP, CFO, SECRY & TREAS. | 60,000 | $12.05 | $723,055 | 722,248 (Direct) | View |
| 2024-05-21 Sale | 2024-05-23 6:54 pm | Y-mAbs Therapeutics Inc. | YMAB | Gad Thomas CHIEF BUSINESS OFFICER | 32,351 | $12.23 | $395,563 | 451,381 (Indirect Direct) | View |
| 2024-03-05 Sale | 2024-03-07 5:02 pm | Y-mAbs Therapeutics Inc. | YMAB | Rajah Vignesh SVP & CHIEF MEDICAL OFFICER | 1,711 | $16.53 | $28,283 | 38,155 (Indirect Direct) | View |
| 2024-03-05 Sale | 2024-03-07 5:01 pm | Y-mAbs Therapeutics Inc. | YMAB | Gad Thomas CHIEF BUSINESS OFFICER | 3,900 | $16.44 | $64,116 | 483,732 (Indirect Direct) | View |
| 2024-03-05 Sale | 2024-03-07 4:59 pm | Y-mAbs Therapeutics Inc. | YMAB | Smith Susan Laura SVP & CHIEF COMMERCIAL OFFICER | 1,682 | $16.55 | $27,837 | 33,918 (Direct) | View |
| 2023-12-13 Sale | 2023-12-15 7:40 pm | Y-mAbs Therapeutics Inc. | YMAB | Gad Thomas Chief Business Officer | 150,000 | $6.6733 | $1,001,000 | 415,532 (Indirect Direct) | View |
| 2023-12-11 Purchase | 2023-12-12 08:27 am | Y-mAbs Therapeutics Inc. | YMAB | WG Biotech ApS Director | 6,455 | $6.8523 | $44,232 | 4,559,233 (Direct) | View |
| 2023-12-11 Purchase | 2023-12-12 08:26 am | Y-mAbs Therapeutics Inc. | YMAB | Wedell-Wedellsborg Johan Director | 6,455 | $6.8523 | $44,232 | 4,559,233 (Indirect) | View |
| 2023-12-07 Purchase | 2023-12-11 5:25 pm | Y-mAbs Therapeutics Inc. | YMAB | WG Biotech ApS Director | 127,549 | $6.9809 | $890,411 | 4,552,778 (Direct) | View |
| 2023-12-07 Purchase | 2023-12-11 5:25 pm | Y-mAbs Therapeutics Inc. | YMAB | Wedell-Wedellsborg Johan Director | 127,549 | $6.9809 | $890,411 | 4,552,778 (Indirect) | View |
| 2023-11-29 Purchase | 2023-12-01 5:15 pm | Y-mAbs Therapeutics Inc. | YMAB | WG Biotech ApS Director | 51,837 | $5.9702 | $309,477 | 4,425,229 (Direct) | View |
| 2023-11-29 Purchase | 2023-12-01 5:14 pm | Y-mAbs Therapeutics Inc. | YMAB | Wedell-Wedellsborg Johan Director | 51,837 | $5.9702 | $309,477 | 4,425,229 (Indirect) | View |
| 2023-11-27 Purchase | 2023-11-29 5:15 pm | Y-mAbs Therapeutics Inc. | YMAB | Wedell-Wedellsborg Johan Director | 93,187 | $5.5941 | $521,294 | 4,373,392 (Indirect) | View |
| 2023-11-27 Purchase | 2023-11-29 5:14 pm | Y-mAbs Therapeutics Inc. | YMAB | WG Biotech ApS Director | 93,187 | $5.5941 | $521,294 | 4,373,392 (Direct) | View |
| 2023-11-20 Sale | 2023-11-22 5:00 pm | Y-mAbs Therapeutics Inc. | YMAB | Gad Thomas Chief Business Officer | 150,000 | $5.3026 | $795,383 | 565,532 (Indirect Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-09-19 Exercise | 2024-09-20 4:15 pm | N/A 2026-10-21 | Y-mAbs Therapeutics Inc. | YMAB | Gad Thomas CHIEF BUSINESS OFFICER | 22,831 | $0 | 452,381 (Direct) | View |
| 2024-09-19 Exercise | 2024-09-20 4:15 pm | N/A N/A | Y-mAbs Therapeutics Inc. | YMAB | Gad Thomas CHIEF BUSINESS OFFICER | 22,831 | $4.38 | 452,381 (Direct) | View |
| 2024-08-28 Exercise | 2024-08-30 4:15 pm | N/A 2026-05-20 | Y-mAbs Therapeutics Inc. | YMAB | Lund-Hansen Torben SVP & CHIEF TECHNICAL OFFICER | 50,000 | $0 | 181,262 (Direct) | View |
| 2024-08-28 Exercise | 2024-08-30 4:15 pm | N/A N/A | Y-mAbs Therapeutics Inc. | YMAB | Lund-Hansen Torben SVP & CHIEF TECHNICAL OFFICER | 50,000 | $4.38 | 181,262 (Direct) | View |
| 2024-07-12 Option Award | 2024-07-12 5:29 pm | N/A 2034-07-12 | Y-mAbs Therapeutics Inc. | YMAB | PFREUNDSCHUH PETER P. CFO and Treasurer | 216,000 | $0 | 216,000 (Direct) | View |
| 2024-06-11 Option Award | 2024-06-13 9:02 pm | N/A 2034-06-11 | Y-mAbs Therapeutics Inc. | YMAB | TAGLIAFERRI MARY Director | 18,040 | $0 | 22,700 (Direct) | View |
| 2024-06-11 Option Award | 2024-06-13 9:02 pm | N/A 2034-06-11 | Y-mAbs Therapeutics Inc. | YMAB | Hamill Laura Director | 18,040 | $0 | 20,370 (Direct) | View |
| 2024-06-11 Option Award | 2024-06-13 9:01 pm | N/A 2034-06-11 | Y-mAbs Therapeutics Inc. | YMAB | Wedell-Wedellsborg Johan Director 10% Owner | 18,040 | $0 | 4,579,603 (Direct) | View |
| 2024-06-11 Option Award | 2024-06-13 9:01 pm | N/A 2034-06-11 | Y-mAbs Therapeutics Inc. | YMAB | HEALY JAMES Director | 18,040 | $0 | 2,240,426 (Direct) | View |
| 2024-06-11 Option Award | 2024-06-13 9:00 pm | N/A 2034-06-11 | Y-mAbs Therapeutics Inc. | YMAB | GILL DAVID N Director | 18,040 | $0 | 20,370 (Direct) | View |
| 2024-06-11 Option Award | 2024-06-13 9:00 pm | N/A 2034-06-11 | Y-mAbs Therapeutics Inc. | YMAB | TYAGI ASHU Director | 18,040 | $0 | 20,370 (Direct) | View |
| 2024-05-30 Exercise | 2024-05-31 9:36 pm | N/A 2025-06-10 | Y-mAbs Therapeutics Inc. | YMAB | Kruse Bo EVP, CFO, SECRY & TREAS. | 60,000 | $0 | 722,248 (Direct) | View |
| 2024-05-30 Exercise | 2024-05-31 9:36 pm | N/A N/A | Y-mAbs Therapeutics Inc. | YMAB | Kruse Bo EVP, CFO, SECRY & TREAS. | 60,000 | $2 | 722,248 (Direct) | View |
| 2024-03-12 Option Award | 2024-03-14 5:01 pm | N/A 2034-03-12 | Y-mAbs Therapeutics Inc. | YMAB | TAGLIAFERRI MARY Director | 32,560 | $0 | 32,560 (Direct) | View |
| 2024-02-12 Option Award | 2024-02-14 4:30 pm | N/A 2034-02-12 | Y-mAbs Therapeutics Inc. | YMAB | Rossi Michael J PRESIDENT & CEO | 303,900 | $0 | 303,900 (Direct) | View |
| 2024-01-18 Option Award | 2024-01-22 6:02 pm | N/A 2034-01-18 | Y-mAbs Therapeutics Inc. | YMAB | Rajah Vignesh SVP & CHIEF MEDICAL OFFICER | 53,500 | $0 | 75,566 (Direct) | View |
| 2024-01-18 Option Award | 2024-01-22 6:00 pm | N/A 2034-01-18 | Y-mAbs Therapeutics Inc. | YMAB | Smith Susan Laura SVP & CHIEF COMMERCIAL OFFICER | 53,500 | $0 | 71,300 (Direct) | View |
| 2024-01-18 Option Award | 2024-01-22 5:58 pm | N/A 2034-01-18 | Y-mAbs Therapeutics Inc. | YMAB | Lisby Steen SVP & CHIEF SCIENTIFIC OFFICER | 53,500 | $0 | 71,300 (Direct) | View |
| 2024-01-18 Option Award | 2024-01-22 5:56 pm | N/A 2034-01-18 | Y-mAbs Therapeutics Inc. | YMAB | Wilms Joris SVP & CHIEF OPERATING OFFICER | 53,500 | $0 | 71,300 (Direct) | View |
| 2024-01-18 Option Award | 2024-01-22 5:54 pm | N/A 2034-01-18 | Y-mAbs Therapeutics Inc. | YMAB | Lund-Hansen Torben SVP & CHIEF TECHNICAL OFFICER | 53,500 | $0 | 116,962 (Direct) | View |
| 2024-01-18 Option Award | 2024-01-22 5:52 pm | N/A 2034-01-18 | Y-mAbs Therapeutics Inc. | YMAB | Gad Thomas CHIEF BUSINESS OFFICER | 154,600 | $0 | 620,132 (Direct) | View |
| 2024-01-18 Option Award | 2024-01-22 5:48 pm | N/A 2034-01-18 | Y-mAbs Therapeutics Inc. | YMAB | Kruse Bo EVP, CFO, SECRY & TREAS. | 127,000 | $0 | 319,777 (Direct) | View |
| 2023-12-21 Exercise | 2023-12-26 4:15 pm | N/A 2025-06-10 | Y-mAbs Therapeutics Inc. | YMAB | Gad Thomas Chief Business Officer | 50,000 | $0 | 568,532 (Direct) | View |
| 2023-12-21 Exercise | 2023-12-26 4:15 pm | N/A N/A | Y-mAbs Therapeutics Inc. | YMAB | Gad Thomas Chief Business Officer | 50,000 | $2 | 568,532 (Direct) | View |